# Phase 3 pancreatic cancer trials recruiting: 35 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials in phase 3 for pancreatic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 pancreatic cancer trials: 35 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/pancreatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 35
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 16, 2026 | NCT07823049 | Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy | Evopoint Biosciences Inc. | Phase 3 | Recruiting | Pancreatic Cancer | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823049) |
| September 8, 2026 | NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic... | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805954) |
| September 4, 2026 | NCT07803783 | A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure... | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 | Not yet recruiting | Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803783) |
| July 8, 2026 | NCT07689539 | Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Pancreatic Cancer | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689539) |
| June 8, 2026 | NCT07632118 | Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery | Tianjin Medical University Cancer Institute and Hospital | Phase 3 | Recruiting | Pancreatic Cancer | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632118) |
| June 2, 2026 | NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic... | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal... | 670 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621718) |
| May 1, 2026 | NCT07562152 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Immuneering Corporation | Phase 3 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal... | 570 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562152) |
| April 13, 2026 | NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal... | Incyte Corporation | Phase 3 | Recruiting | Solid Tumors | 588 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522073) |
| March 24, 2026 | NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal... | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07491445) |
| February 13, 2026 | NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With... | Astellas Pharma Global Development, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma | 614 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409272) |
| February 3, 2026 | NCT07383922 | A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Phase 3 | Not yet recruiting | Pancreatic Cancer | 524 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07383922) |
| December 9, 2025 | NCT07272109 | Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes | Fudan University | Phase 3 | Not yet recruiting | Pancreatic Cancer | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07272109) |
| December 3, 2025 | NCT07262567 | Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer | Genfleet Therapeutics (Shanghai) Inc. | Phase 3 | Recruiting | Metastatic Pancreatic Cancer | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262567) |
| November 26, 2025 | NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)... | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252232) |
| August 24, 2025 | NCT07138846 | A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced... | Lepu Biopharma Co., Ltd. | Phase 3 | Not yet recruiting | Advanced Pancreatic Cancer | 231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07138846) |
| July 23, 2025 | NCT07081360 | Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer | Minia University | Phase 3 | Recruiting | Pancreas Cancer, Periampullary Cancer, Periampullary Carcinoma Resectable, Pancreatic Cancer Resectable, Ampullary... | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07081360) |
| July 22, 2025 | NCT07079228 | A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Pancreatic Cancer | 602 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07079228) |
| July 15, 2025 | NCT07066098 | A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic... | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Pancreatic Cancer | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07066098) |
| May 31, 2025 | NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | SWOG Cancer Research Network | Phase 3 | Recruiting | Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8... | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06998940) |
| May 6, 2025 | NCT06958328 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | NRG Oncology | Phase 3 | Recruiting | Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III... | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06958328) |
| May 1, 2025 | NCT06953999 | A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | Akeso | Phase 3 | Recruiting | Pancreatic Cancer | 999 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06953999) |
| March 27, 2025 | NCT06897644 | Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With... | Gruppo Oncologico del Nord-Ovest | Phase 3 | Recruiting | Pancreatic Adenocarcinoma Advanced or Metastatic | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06897644) |
| March 6, 2025 | NCT06861088 | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | Quercis Pharma AG | Phase 3 | Recruiting | Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06861088) |
| February 4, 2025 | NCT06807437 | Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | SWOG Cancer Research Network | Phase 3 | Recruiting | Pancreatic Carcinoma, Pancreatic Neoplasm | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06807437) |
| December 3, 2024 | NCT06714604 | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC | Sahlgrenska University Hospital | Phase 3 | Recruiting | Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer, Neoadjuvant... | 432 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06714604) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 4 |
| Fudan University | 3 |
| SWOG Cancer Research Network | 2 |
| Case Comprehensive Cancer Center | 1 |
| Lepu Biopharma Co., Ltd. | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| Gruppo Oncologico del Nord-Ovest | 1 |
| [CSPC Ouyi Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-ouyi-pharmaceutical-co-ltd) | 1 |
| [Evopoint Biosciences Inc.](https://specstream.ai/data/clinical-trials/company/evopoint-biosciences-inc) | 1 |
| M.D. Anderson Cancer Center | 1 |
| Changhai Hospital | 1 |
| [MediLink Therapeutics (Suzhou) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/medilink-therapeutics-suzhou-co-ltd) | 1 |
| Sahlgrenska University Hospital | 1 |
| Jiangxi Kvvit Pharmaceutical Co., Ltd. | 1 |
| Immuneering Corporation | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 1 |
| Minia University | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| Johns Hopkins University | 1 |
| NRG Oncology | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Quercis Pharma AG | 1 |
| GC Cell Corporation | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 14 |
| United Kingdom | 6 |
| Germany | 5 |
| Italy | 5 |
| South Korea | 5 |
| Spain | 5 |
| Canada | 4 |
| France | 4 |
| Japan | 4 |
| Poland | 4 |
| Sweden | 4 |
| Australia | 3 |
| Austria | 3 |
| Netherlands | 3 |
| Belgium | 2 |
| Denmark | 2 |
| Georgia | 2 |
| Norway | 2 |
| Puerto Rico | 2 |
| Switzerland | 2 |
| Brazil | 2 |
| Taiwan | 2 |
| Finland | 1 |
| New Zealand | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Salad bars in the United States](https://specstream.ai/data/businesses/salad-bars/united-states)
- [Scale suppliers in the United States](https://specstream.ai/data/businesses/scale-suppliers/united-states)
- [Seafood wholesalers in the United States](https://specstream.ai/data/businesses/seafood-wholesalers/united-states)
- [Shared office spaces in the United States](https://specstream.ai/data/businesses/shared-office-spaces/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
- [Sleep medicine clinics in the United States](https://specstream.ai/data/businesses/sleep-medicine-clinics/united-states)
